CHRS Company Profile and Key Details
NASDAQ : CHRS
Coherus Oncology
$1.48
-0.01-0.67%
At Close 4:00 PM60.2
BESG ScoreESG Rating
Price Chart
Stock Price Today
Coherus Oncology, Inc. (CHRS) stock declined over -0.67%, trading at $1.48 on NASDAQ, down from the previous close of $1.49. The stock opened at $1.48, fluctuating between $1.46 and $1.51 in the recent session.
Stock Snapshot
1.49
Prev. Close
181.17M
Market Cap
1.46
Day Low
-1.04
P/E Ratio
-1.42
EPS (TTM)
-1.57
Cash Flow per Share
1.48
Open
122.41M
Number of Shares
1.505
Day High
95.66%
Free Float in %
-1.73
Book Value
1.37M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 19, 2026 | 1.49 | 1.51 | 1.46 | 1.48 | 1.37M |
| May 18, 2026 | 1.57 | 1.60 | 1.46 | 1.49 | 1.77M |
| May 15, 2026 | 1.61 | 1.65 | 1.56 | 1.57 | 1.51M |
| May 14, 2026 | 1.70 | 1.74 | 1.63 | 1.63 | 1.98M |
| May 13, 2026 | 1.73 | 1.79 | 1.60 | 1.71 | 2.41M |
| May 12, 2026 | 1.75 | 1.82 | 1.62 | 1.71 | 3.46M |
| May 11, 2026 | 1.89 | 2.11 | 1.87 | 1.95 | 3.67M |
| May 08, 2026 | 1.77 | 1.80 | 1.74 | 1.75 | 665.83K |
| May 07, 2026 | 1.76 | 1.77 | 1.71 | 1.76 | 919.25K |
| May 06, 2026 | 1.81 | 1.87 | 1.75 | 1.75 | 1.28M |
| May 05, 2026 | 1.74 | 1.80 | 1.74 | 1.79 | 874.53K |
| May 04, 2026 | 1.78 | 1.82 | 1.73 | 1.73 | 717.08K |
| Apr 30, 2026 | 1.74 | 1.83 | 1.74 | 1.78 | 513.52K |
| Apr 29, 2026 | 1.75 | 1.75 | 1.70 | 1.74 | 658.68K |
| Apr 28, 2026 | 1.79 | 1.86 | 1.76 | 1.77 | 624.13K |
| Apr 27, 2026 | 1.75 | 1.89 | 1.74 | 1.84 | 1.03M |
| Apr 23, 2026 | 1.81 | 1.81 | 1.69 | 1.76 | 1.38M |
| Apr 22, 2026 | 1.85 | 1.85 | 1.78 | 1.80 | 815.83K |
| Apr 21, 2026 | 1.98 | 2.00 | 1.81 | 1.82 | 1.94M |
| Apr 20, 2026 | 1.96 | 2.02 | 1.93 | 1.99 | 761.75K |
Contact Details
About Company
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Company Information
| Employees | 228 |
| Beta | 1.04 |
| Sales or Revenue | $257.24M |
| 5Y Sales Change% | 113.144% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
21.51+2.77%
argenx SE$797.77REGN0.62+0.10%
Regeneron Pharmaceuticals, Inc.$630.30UTHR-0.19-0.03%
United Therapeutics Corporation$566.80MDGL-10.41-1.99%
Madrigal Pharmaceuticals, Inc.$511.82VRTX-2.27-0.52%
Vertex Pharmaceuticals Incorporated$434.31KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83PRAX0.08+0.02%
Praxis Precision Medicines, Inc.$320.61ALNY8.03001+2.81%
Alnylam Pharmaceuticals, Inc.$294.30KRYS1.55+0.53%
Krystal Biotech, Inc.$293.30ASND0.34+0.14%
Ascendis Pharma A/S$237.98Company Overview
Coherus Oncology, Inc. (NASDAQ:CHRS) closed at $1.48 USD, losing -$0.01 (-0.67%) from the previous close of $1.49. The stock is currently mid-range between its 52-week high and low $0.71 and $2.62. With a market capitalization of about $181.17 million, Coherus Oncology, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.02). Key stats such as the average daily volume over the past year has been around 1.29 million shares, in line with its 52-week average. Headquartered in Redwood City, CA, Coherus Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dennis Lanfear, the company employs approximately 228 people and listed since November 06, 2014. Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Technical Performance
Short-term trend indicators are bearishly aligned (SMA20 -11.98%, SMA50 -1.38%, SMA200 29.78%). The stock’s 14-day RSI is 44.55 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -35.39% below its high and over 138.03% above its low. Average 10-day trading volume of 2.31 million shares is significantly above the 3-month average of 1.32 million, indicating heightened recent market interest.
Valuation Metrics
Coherus Oncology, Inc. trades at a P/E ratio of -1.32, slightly below the S&P 500 average, with a price-to-sales ratio of 3.84 and a price-to-book ratio of 2.55 suggesting the stock is closer to book value. The P/FCF stands at -1.05, also above market averages.
Dividend & Fair Value
Coherus Oncology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.30. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Coherus Oncology, Inc. generated EPS of -$1.59 over the past year. Five-year average earnings growth is -27.36%. The latest quarter delivered EPS of -$0.27. The next quarter is forecast at -$0.36. Next year's EPS is expected at $75.46. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $4.00. The high target offers 575.68% upside. The low target suggests 170.27% downside. The mean target is $7.00. This offers 372.97% upside. Coherus Oncology, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 2.53%. The prior quarter beat by -4.25%. Over the last six quarters, Apple has recorded several small beats. These include 180.0% in March 10, 2025.
Shareholding & Insider Activity
Coherus Oncology, Inc. has 116.23 million shares outstanding. The public float is 111.19 million shares, elevated short interest at 28.57% of float. This equals 31.93 million shares. The short ratio is 23.19 days. Institutional investors hold 50.85% of the float. Insiders own 6.52%. Lanfear Dennis M holds 731.69 thousand shares, Viret Jean-Frederic has 61.30 thousand shares and Anicetti Vincent R has 53.40 thousand shares.
Financial & Profitability Overview
On valuation metrics, Coherus Oncology trades at a P/E of -1.32, P/S of 3.84 and P/B of 2.55. The current ratio is 1.56 and quick ratio is 1.52. Operationally, the company’s inventory turnover is 3.88 and cash conversion cycle is 45.61 days. Debt-to-equity is 0.69, supported by a cash flow-to-debt ratio of -3.14.
Quarterly Financial Highlights
The company ended the quarter with $117.75M in cash and short-term investments, a total debt of $480.84M, and net debt of $377.95M. Total assets were $629.60M, with equity of - $193.43M. Financials further reflected weakness, with operating cash flow of - $174.88M, free cash flow of - $175.17M, and capital expenditures of - $286.00K.
Price Forecast & Outlook
Our AI price prediction model suggests that Coherus Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.38%, with price expected at $1.43 by June 02, 2026, within a range of $1.33 to $1.53 3-Month Outlook: Projected fall of -30.41%, reaching $1.03 by August 17, 2026, with a range of $0.91 to $1.13. 1-Year Outlook: Projected gain of 494.59%, with price at $8.80 by May 19, 2027, within a range of $4.75 to $10.58.
Key Takeaways
Coherus Oncology, Inc. (NASDAQ:CHRS) shares are flat 9.15% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Coherus Oncology, Inc. trading at a premium to the broader market with a P/E of -1.32. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $19.42, suggesting 1212.16% upside. Our AI forecast model points to short-term weakness (-3.38% over two weeks), a medium-term fall (-30.41% over three months), and a longer-term gain (494.59% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Coherus Oncology, Inc. (CHRS) stock price?
Coherus Oncology, Inc. (NASDAQ: CHRS) stock price is $1.48 in the last trading session. During the trading session, CHRS stock reached the peak price of $1.51 while $1.46 was the lowest point it dropped to. The percentage change in CHRS stock occurred in the recent session was -0.67% while the dollar amount for the price change in CHRS stock was - $0.01.
CHRS's industry and sector of operation?
The NASDAQ listed CHRS is part of Biotechnology industry that operates in the broader Healthcare sector. Coherus Oncology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of CHRS?
Ms. Karen Kotz
Executive Vice President of Sales & Strategic Accounts
Mr. Bryan J. Mcmichael
Senior Vice President of Accounting, Principal Accounting Officer & Corporation Controller
Mr. Richard L. Hameister
Chief Technical Officer
Mr. Christopher W. Slavinsky
Chief Bus. & Legal Officer
Mr. Dennis M. Lanfear
Chairman, Pres & Chief Executive Officer
Mr. Vladimir Vexler Ph.D.
Chief Scientific Officer
Mr. McDavid Stilwell
Chief Financial Officer
Cheston Turbyfill
Vice President of Communications
Dr. Lee Mermelstein Ph.D.
Executive Vice President of Manufacturing
Ms. Rebecca Sunshine
Chief HR Officer
Mr. Paul Reider
Chief Commercial Officer
Executive Vice President of Sales & Strategic Accounts
Mr. Bryan J. Mcmichael
Senior Vice President of Accounting, Principal Accounting Officer & Corporation Controller
Mr. Richard L. Hameister
Chief Technical Officer
Mr. Christopher W. Slavinsky
Chief Bus. & Legal Officer
Mr. Dennis M. Lanfear
Chairman, Pres & Chief Executive Officer
Mr. Vladimir Vexler Ph.D.
Chief Scientific Officer
Mr. McDavid Stilwell
Chief Financial Officer
Cheston Turbyfill
Vice President of Communications
Dr. Lee Mermelstein Ph.D.
Executive Vice President of Manufacturing
Ms. Rebecca Sunshine
Chief HR Officer
Mr. Paul Reider
Chief Commercial Officer
How CHRS did perform over past 52-week?
CHRS's closing price is 108.45% higher than its 52-week low of $0.71 where as its distance from 52-week high of $2.62 is -43.42%.
How many employees does CHRS have?
Number of CHRS employees currently stands at 228.
Link for CHRS official website?
Official Website of CHRS is: https://www.coherus.com
How do I contact CHRS?
CHRS could be contacted at phone 650 649 3530 and can also be accessed through its website. CHRS operates from 333 Twin Dolphin Drive, Redwood City, CA 94065, United States.
How many shares of CHRS are traded daily?
CHRS stock volume for the day was 1.37M shares. The average number of CHRS shares traded daily for last 3 months was 1.29M.
What is the market cap of CHRS currently?
The market value of CHRS currently stands at $181.17M with its latest stock price at $1.48 and 122.41M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep